-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Over time, Bacille Calmette-Guérin (BCG) has evolved into different types and is used in intravesical immunotherapy for non-muscle-invasive bladder cancer (NMIBC)
Some comparative clinical studies have shown differences in therapeutic effect between selected strains
VPM1002BC is a transgenic M.
To investigate the efficacy, safety, tolerability and quality of life of recurrent non-muscle invasive bladder cancer (NMIBC) after intravesical injection of VPM1002BC in the treatment of conventional BCG therapy.
The researchers designed a phase 1/2 single-arm trial (NCT02371447)
After excluding 2 ineligible patients, 40 patients were included in the full analysis group
Relapse-free rate at 60 weeks of treatment
Relapse-free rate at 60 weeks of treatmentIn conclusion, almost half of the patients did not relapse after treatment with VPM100BC 1 year after the start of treatment
Almost half of the patients did not relapse after treatment with VPM100BC 1 year after the start of treatment Almost half of the patients did not relapse after treatment with VPM100BC 1 year after the start of treatment
Original source:
Original source:Cyrill A Rentsch, George N Thalmann, Ilaria Lucca et al.
leave a message here